

Roderich E Schwarz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8123432/publications.pdf>

Version: 2024-02-01

54
papers

1,676
citations

331642

21
h-index

276858

41
g-index

55
all docs

55
docs citations

55
times ranked

2793
citing authors

#	ARTICLE	IF	CITATIONS
1	Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1149-1159.	4.1	3
2	Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4950-4961.	3.6	8
3	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. <i>Cancer Letters</i> , 2019, 459, 41-49.	7.2	35
4	Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in preclinical models of pancreatic cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3878-3887.	3.6	22
5	Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 17608.	3.3	11
6	Physician derived versus administrative data in identifying surgical complications. Fact versus Fiction. <i>American Journal of Surgery</i> , 2019, 217, 447-451.	1.8	5
7	Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. <i>Translational Oncology</i> , 2018, 11, 426-435.	3.7	21
8	Quality measurement affecting surgical practice: Utility versus utopia. <i>American Journal of Surgery</i> , 2018, 215, 357-366.	1.8	10
9	Clinical trends and effects on quality metrics for surgical gastroesophageal cancer care. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 43-43.	3.0	3
10	Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility. <i>Biochemical Pharmacology</i> , 2018, 156, 458-466.	4.4	22
11	Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2353-2364.	4.1	11
12	Simplicity and Safety: Minimized Pancreatic Fistula Rate after Distal Pancreatectomy through Pancreas Stump Sutured Fish-Mouth Closure. <i>American Surgeon</i> , 2018, 84, 1734-1740.	0.8	2
13	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 5274-5286.	1.8	24
14	Managing the Unmanageable: A Two-Stage Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent Paraganglioma. <i>American Journal of Case Reports</i> , 2018, 19, 386-391.	0.8	2
15	Institutional variants for lymph node counts after pancreatic resections. <i>American Journal of Surgery</i> , 2017, 214, 437-441.	1.8	0
16	A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0171824.	2.5	10
17	Vascular challenges from pancreatoduodenectomy in the setting of coeliac artery stenosis. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016217943.	0.5	3
18	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 218-224.	1.5	61

#	ARTICLE	IF	CITATIONS
19	Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. <i>Oncotarget</i> , 2016, 7, 46988-47001.	1.8	10
20	Experience with a simple clamp-crush technique devoid of other devices for liver resections in a surgical oncology practice. <i>American Journal of Surgery</i> , 2015, 209, 503-508.	1.8	1
21	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. <i>Cancer Letters</i> , 2015, 359, 335-343.	7.2	82
22	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015, 358, 59-66.	7.2	48
23	Current Status of Management of Malignant Disease: Current Management of Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 782-788.	1.7	27
24	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1032-1043.	4.1	19
25	Biliary obstruction and postoperative morbidity after pancreatoduodenectomy: what still obstructs clearance to clearance of obstruction. <i>American Journal of Surgery</i> , 2014, 208, 11-12.	1.8	0
26	Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes. <i>Chinese Medical Journal</i> , 2014, 127, 435-41.	2.3	6
27	Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. <i>Hpb</i> , 2013, 15, 106-115.	0.3	44
28	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. <i>Carcinogenesis</i> , 2013, 34, 2361-2369.	2.8	107
29	Antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 33-33.	1.6	1
30	Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 332-332.	1.6	1
31	Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 192-192.	1.6	1
32	The efficacy of a novel, dual PI3K/mTOR inhibitor NVPâ€BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 784-791.	2.6	78
33	Potential factors to explain decreased survival for ethnic subgroups with gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 12-12.	1.6	1
34	Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 170-170.	1.6	2
35	Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e38477.	2.5	32
36	Clinical Evidence: Metastases can Metastasize. <i>World Journal of Oncology</i> , 2012, 3, 138-141.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model.. Journal of Clinical Oncology, 2012, 30, 230-230.	1.6	0
38	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.. Journal of Clinical Oncology, 2012, 30, 234-234.	1.6	0
39	Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer, 2011, 11, 15.	2.6	26
40	Challenges with Demographic Disparities in Gastric Cancer Care and Survival: Spectral Rather than Black and White. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 221-222.	2.5	0
41	Transplantation for hepatocellular carcinoma as part of a balanced, multidisciplinary strategy. Oncology, 2011, 25, 761-3.	0.5	0
42	EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 1442-1452.	1.5	24
43	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. Hpb, 2010, 12, 313-320.	0.3	68
44	Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biology and Therapy, 2010, 9, 632-639.	3.4	32
45	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery, 2009, 146, 241-249.	1.9	15
46	Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. American Journal of Surgery, 2008, 195, 829-836.	1.8	92
47	Factors influencing change of preoperative treatment intent in a gastrointestinal cancer practice. World Journal of Surgical Oncology, 2007, 5, 32.	1.9	8
48	Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Annals of Surgical Oncology, 2007, 14, 317-328.	1.5	231
49	Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas, Based on U.S. Population Data. Journal of Gastrointestinal Surgery, 2007, 11, 158-165.	1.7	53
50	Clinical Impact of Lymphadenectomy Extent in Resectable Esophageal Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 1384-1394.	1.7	128
51	Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database. Annals of Surgical Oncology, 2006, 13, 1189-1200.	1.5	209
52	Hypomagnesemia after Major Abdominal Operations in Cancer Patients: Clinical Implications. Archives of Medical Research, 2005, 36, 36-41.	3.3	21
53	Complications of Malignancy. Journal of Clinical Oncology, 2004, 22, 373-374.	1.6	5
54	An orthotopic in vivo model of human pancreatic cancer. Surgery, 1999, 126, 562-567.	1.9	48